Table 3.

Results of SIR analyses for the BE cohort

Cancer incidence (ICD-10 code)ObservedExpectedSIR (95% CI)
All malignant neoplasms (C00-C97) excluding NMSCs (C44)7264.141.12 (0.88-1.41)
All malignant neoplasms (C00-C97) excluding NMSCs (C44) and esophageal malignancy (C15)5862.530.93 (0.70-1.20)
    Malignant neoplasm of digestive organs (C15-C26)3217.231.86* (1.27-2.62)
    Malignant neoplasm of digestive organs excluding esophagus (C16-C26)1815.611.15 (0.68-1.82)
    Malignant neoplasm of esophagus (C15)141.628.66 (4.73-14.53)
    Malignant neoplasm of esophagus (C15) and stomach (C16)215.054.16 (2.57-6.37)
    Esophageal adenocarcinoma (C15:81403)110.7714.29 (7.13-22.56)
    Esophageal adenocarcinoma (C15:81403+80103)140.7718.18 (9.94-30.51)
    Malignant neoplasm of colon, rectosigmoid junction and anus (C18-C21)89.210.87 (0.38-1.71)
    Malignant neoplasm of trachea, bronchus and lung (C33-C34)1412.341.13 (0.62-1.90)
  • NOTE: 95% CIs are Poisson exact. Incidence cancers and ICD-10 codes for individuals only included in the “All-malignant” categories of analysis include malignant neoplasms of connective and soft tissue (C498), breast (C509, n = 2), corpus uteri (C541, C549; n = 2), prostate (C61; n = 6), kidney (C64), eye, brain, and other parts of the central nervous system (C699, C713, C73), ill-defined, secondary, and unspecified sites (C785, C787; n = 2, C792, C793, C80; n = 2), lymphoid, hematopoietic and related tissue (C833, C900; n = 2). These cancers were not analyzed in a specific category due to limited numbers.

  • * Twice, one-sided P < 0.01.

  • Twice, one-sided P < 0.001.

  • Histology 80103 (carcinoma) is assumed to be adenocarcinoma (81403) in this analysis.